RT Journal Article
SR Electronic
A1 Helwick, Caroline
T1 Imatinib Dose Interruption in GIST: High Progression Risk for 3-Year Responders
JF MD Conference Express
YR 2007
FD SAGE Publications
VO 7
IS 3
SP 30
OP 34
DO 10.1177/155989770700700312
UL http://mdc.sagepub.com/content/7/3/30.abstract
AB This article discusses multiple clinical trials using imatinib for the treatment of gastrointestinal stromal tumor (GIST). Specific topics include the risk associated with the interruption of imatinib therapy among advanced GIST patients, the link between higher doese of imatinib for GIST and longer progression-free survival, as well as the use of imatinib for recurrence-free survival in completely resected GIST.